Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/2/2008

nts studied in ATHENA were either 75 years of age or older (with or without cardiovascular risk factor) or above 70 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40%). Patients were randomized to receive Multaq(R) 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of Multaq(R) on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalisation for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

The ATHENA stroke post-hoc analysis on a non-pre-specified secondary endpoint was conducted in order to confirm the consistent benefit of Multaq(R) in atrial fibrillation or atrial flutter patients in reducing major cardiovascular complications like stroke, which is a leading cause of cardiovascular hospitalizations or death in this patient population.

About Multaq(R) (dronedarone)

Multaq(R) is an investigational treatment and the only anti-arrhythmic drug (AAD) to have shown a significant reduction in morbidity and mortality in atrial fibrillation /atrial flutter patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity.

Multaq(R), discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 7,000 patients. Multaq(R) is one of the major therapeutic innov
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
2. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
3. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
4. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
5. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
6. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
10. Arpida Provides Further Comments on the Pivotal Phase III Trials
11. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/23/2014)... Hopkins scientists report that rats exposed to high-energy particles, ... space mission, show lapses in attention and slower reaction ... low dose ranges. , The cognitive impairments which ... the animals appear to be linked to protein ... if found to hold true in humans, suggest it ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... area of the gastro-intestinal tract has long been considered ... at the Sahlgrenska Academy have used refined microscopic techniques ... inner surface of the gastro-intestinal tract is only as ... Fndriks. , The digestive tract, which passes from the ... has a length of about 5 meters in a ...
(Date:4/23/2014)... predict which patients might suffer potentially fatal side-effects from ... assesses brain scans using pattern recognition software similar to ... been developed by researchers at Imperial College London. Results ... which used the software are published in the journal ... 15 million people each year worldwide. Ischemic strokes are ...
(Date:4/23/2014)... Bethesda, MD (April 23, 2014) The American ... announce the 2014 AGA Research Scholars. The AGA ... young investigators to develop independent and productive research ... Research Scholar Awards fund an additional year allowing ... is committed to supporting junior faculty who are ...
Breaking Medicine News(10 mins):Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:AGA announces 2014 Class of AGA Research Scholars 2
... Supreme Court today issued notices to the Centre and Medical Council ... by doctors. // ,A bench of Justice Arijit Pasayat ... respond to the PIL filed by People for Better Treatment, within ... file its rejoinder to the replies of Centre and MCI., ...
... Lebanon will not have to wait for access to public ... it will waive the mandatory three-month waiting period for OHIP ... the Health Minister George Smitherman the evacuees have undergone a ... the "health care they need when they need it the ...
... deaths in municipal hospitals in Mumbai from Saturday morning ... and another of suspected leptospirosis.// ,The Brihanmumbai ... on Sunday with various diseases — 208 with fever, ... vomiting,; 10 of 'suspected dengue', 19 with jaundice and ...
... BMA Cymru Wales' response to growing concerns amongst Welsh ... ,Launching the guidance document, chairman of ... “Unwanted and unprofessional behaviour in the workplace that is ... suffer from bullying and harassment like any other profession. ...
... the country do not disclose their status at workplaces ... ,"Seventy-four per cent of the employees have ... the remaining 26 per cent who have disclosed their ... the hands of the employer," a UNDP-NACO-NCAER report on ...
... organizations urge anyone over age 65 to get yearly ... preventing flu and its complications among older adults, according ... ,Similarly, there is a little evidence that vaccinating healthcare ... study found. ,The reviews appear in the ...
Cached Medicine News:Health News:Doctors' Bid to End Bullying and Harassment in the Workplace 2Health News:Only Modest Benefit of Flu Shots Among Older Adults 2Health News:Only Modest Benefit of Flu Shots Among Older Adults 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: